MICROBIOTA MODULATION TO REDUCE CARDIOVASCULAR RISK IN HIV PATIENTS: A SYSTEMATIC REVIEW

Villoslada-Blanco Pablo¹, Pérez-Matute Patricia², Oteo José A.³

¹Infectious Diseases, Microbiota and Metabolism Unit. Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain. ORCID: 0000-0002-1220-5228

²Infectious Diseases, Microbiota and Metabolism Unit. Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain. ORCID: 0000-0003-2232-7971

³Infectious Diseases Department. Hospital San Pedro, Logroño, La Rioja, Spain. Infectious Diseases, Microbiota and Metabolism Unit. Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja Spain. ORCID: 0000-0001-7080-6542

Corresponding author: cpperez@riojasalud.es
Infectious Diseases, Microbiota and Metabolism Unit
Infectious Diseases Department
Center for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain
ABSTRACT

Background: human immunodeficiency virus (HIV) infection is associated with premature and accelerated aging linked to the development of several co-morbidities, such as cardiovascular events, even after controlling for traditional cardiovascular risk factors. Since both traditional and “novel” factors are involved in the increased cardiovascular risk (CVR) observed in HIV-infected patients, new biomarkers could be needed to diagnose, evaluate and prevent the evolution of these events. Furthermore, since microbiota disturbance is involved in HIV-associated co-morbidities, all strategies focused on reversing or modulating gut microbiota (GM) composition and/or functionality could be of interest. In this context, a solid scientific evidence based on well-designed clinical trials is needed to support the use of prebiotics, probiotics, symbiotics and fecal transplantation (FT) to modify GM in HIV-infected patients and, therefore, to reduce the incidence of cardiovascular disease (CVD) in this population.

Methods: a search in PubMed has been carried out covering all clinical trials (Clinical Trial filter) including adult humans (19+ years) and whose results have been published in the last 10 years. Besides, the results obtained from ClinicalTrials.gob have been included and described in the present review Thus, we have reviewed the main results obtained from 3 clinical trials concerning the effects of prebiotics, 25 concerning probiotics, 6 concerning symbiotics and 4 concerning FT.

Results: none of the trials included in this review investigated if these compounds were able to reduce cardiovascular events in HIV patients.

Conclusions: the huge variability observed in the type of compound used, the dose and the length of administration, makes difficult to analyse the results as a proper meta-
analysis and, therefore, to adopt general recommendations. Thus, there is an urgent need to investigate in this direction through robust and well-designed clinical trials.

KEYWORDS

HIV infection, aging, cardiovascular risk, gut microbiota, prebiotics, probiotics, symbiotics, fecal transplantation.
BACKGROUND

In last decades, life expectancy in human immunodeficiency virus (HIV) infection has significantly increased thanks to the improvement in clinical management and, specially, by the extended use of antiretroviral therapy (ART). Indeed, to date, HIV infection is considered a chronic disease, although life expectative is not as long as that observed in non-infected people or general population (1). This fact has been associated with premature and accelerated aging, among other factors (2). The acceleration of the aging process leads to immunosenescence, which is characterized by continuous activation of the immune system and a low-grade chronic inflammation (3). Thus, HIV patients are predisposed to co-morbidities and natural aging symptoms more frequently seen in elderly people. Therefore, HIV patients have higher rates of cardiovascular disease (CVD), mainly atherosclerosis, and also non-AIDS (acquired immune deficiency syndrome) cancers, frailty (loss of muscle mass, osteoporosis and muscle weakness), kidney or liver diseases and neurologic complications such as dementia, compared to uninfected subjects of the same age (4–10). As an example, several studies have demonstrated that HIV infection is associated with a 50% increased risk of acute myocardial infarction (AMI) beyond that explained by recognized/”classical” risk factors (4,11–13). In fact, recent studies have looked above traditional CVR factors expanding the view towards immunology, intestinal microbiome, red blood cells and endothelial function (14–17) disorders among others. Thus, the presence of factors others than “classical” cardiovascular risk (CVR) factors makes necessary to study in depth the physiopathology of these processes in the context of HIV infection. In addition, interventions to modify both traditional and “novel” risk factors are urgently needed in HIV people in order to reduce future adverse events and, therefore, to counteract the consequences of the accelerated aging and to improve their quality of life (18).
In this context, one “novel” factor recently associated with cardiovascular events in HIV-infected patients but also in the general population is gut microbiota (GM). Microbiota is the community of microorganisms which coexist in a specific environment, including bacteria, archaea, viruses and some unicellular eukaryotes (19,20). There are lots of studies that have demonstrated that alterations in GM play an important role in health and disease (21,22). Nowadays, the development of next-generation sequencing technologies allows the identification of new markers of the physiological and pathological state of each individual, which enables an approximation and a description of GM in different medical disorders (23–26). However, it is still not well established if modifications in GM are cause or consequence of the alterations in health and, therefore, every disorder should be separately and deeply analyzed. In the context of HIV, this infection is characterized by a set of structural changes of the gut epithelial barrier, immunological shifts and also modifications in the composition and functionality of the GM. In normal physiological conditions, the microorganisms are in the intestinal lumen interacting with the intestinal cells in a state of symbiosis but, when HIV infection occurs, depletion of lymphocytes T CD4 takes place in the gut-associated lymphoid tissue (GALT). This is accompanied by a rupture of the epithelial barrier, which triggers alterations in the intestinal lumen and also in the composition of the microbiota (at least at bacteria level) (27). This dysbiosis favors the passage of microorganisms and their components to the lamina propia and, hence, to the circulation, which is known as bacterial translocation (BT), which undergoes subsequent intestinal and systemic inflammation (28) (Fig1).

Dysbiosis is observed in HIV infection. Thus, all strategies focused on reversing or modulating GM composition and/or functionality could be of interest. Prebiotics, probiotics, symbiotics and even fecal transplantation (FT) have emerged as “novel”
promising therapies to control/reverse the changes observed in GM composition in HIV infection and to reduce the incidence of co-morbidities such as cardiovascular events or obesity (29–32). Nevertheless and despite the good reputation of these interventions in several recurrent diseases others than HIV infection, such as non-alcoholic fatty liver disease (NAFLD) (33), obesity (34,35), irritable bowel syndrome (I) (36) and *Clostridioides difficile* infection (37), it is necessary to show solid scientific evidences in order to recommend their use in a specific population such as HIV-infected people. Also, it is necessary to know which are the optimal dose, route, administration frequency and exact composition. In fact, in 2001 an expert commission gathered by the Food and Agriculture Organization (FAO) and the World Health Organization (WHO) recognised the need of establishing guidelines for the evaluation of the efficacy and safety of probiotics (38), taking into account the evaluation of the toxicity and functionality of the strain using both *in vitro, ex vivo* and *in vivo* trials, and especially phase 2 and phase 3 clinical trials [34-35]. Concerning prebiotics, the regulation is far less strict because they are natural components. In the case of FT, the Food and Drug Administration (FDA) has to firstly answer a serious problem about if stool is a drug, a body tissue or a little of both (39) for a proper regulation, which seems to be different depending on the country. In addition, on June 13, 2019, the FDA issued a FT warning after 2 immunocompromised adults who received investigational FT developed invasive infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. To prevent similar problems in the future, the FDA now recommends screening donors in order to see if they are at risk of carrying multi-drug-resistant organisms (MDROs) (40). Thus, more studies are needed to control all these variables and to make clear recommendations to the general population or to specific groups, such as HIV-infected people.
METHODS

The objectives of this review were, i) to summarize the link between HIV infection and CVDs with special emphasis on GM involvement; ii) to describe “novel” biomarkers for cardiovascular risk in HIV infected patients; iii) to investigate if there is a solid scientific evidence (based on well-designed clinical trials) that supports the use of prebiotics, probiotics, symbiotics and FT to modify GM in HIV-infected patients. To achieve the last objective a search in PubMed has been carried out covering all clinical trials (Clinical Trial filter) including adult humans (19+ years) and whose results have been published in the last 10 years. We have limited the search to clinical trials because they are in the top of the “pyramid of scientific evidence”, just below meta-analysis and systematic reviews (41). Meta-analyses and systematic reviews have also been consulted to confirm the clinical trials chosen for this review. A ten-years period has been chosen because from the 688 results obtained in PubMed with the keywords “microbiota HIV”, 657 were published in the last 10 years, which means a huge and representative proportion (95.49%) of the total investigation developed in this field. Besides, a search in ClinicalTrials.gob has also been carried out and these studies have also been included and described in the present review (42).
RESULTS

1. CARDIOVASCULAR DISEASE IN HIV-INFECTED PATIENTS: FOCUS ON ATHEROSCLEROSIS

In this review, we have focused on atherosclerosis due to the fact that it constitutes a risk "per se" of developing other CVDs such as heart attack or stroke both in the general population as well as in HIV-infected patients. There are few differences in the histology of the atheromatous plaques of necropsy studies between HIV patients and uninfected patients, which suggests that the physiopathology of the development of the atheromatous plaque is quite similar (43) and consists on the well-known 3 phases: i) leukocyte infiltration into the subendothelial space and endothelial dysfunction, ii) formation of the lipid core of the atheromatous plaque, and iii) destabilization of the atheromatous plaque (44). Thus, we assume that the same CVR factors that contribute to the development of atherosclerosis affecting general population will also affect HIV-infected patients. The role of these traditional CVR factors in the development of cardiovascular events in HIV-infected people have been brilliantly reviewed by others (45).

In addition to the "classical" CVR factors, some authors consider that HIV infection acts as a CVR factor "per se". At vascular level, during leukocyte (mainly lymphocytes and macrophages) infiltration into the subendothelial space, leukocytes from HIV-infected patients have greater penetration capacity (46), possibly due to the fact that viral protein TAT increase the permeability of the vascular endothelium (47). Once installed in the subendothelial space, the lymphocytes get in contact with the endothelial cells, and these induce a significant increase of the viral replication inside the lymphocytes (through major histocompatibility complex (MHC) class II – T-cell receptors (TCRs) interaction) and, therefore, of the expression of viral proteins (48). The endothelial cells in contact with the viral protein TAT show more expression of
macrophage attracting cytokines such as monocyte chemoattractant protein 1 (MCP-1/CCL2) (49) and adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) (50), which attracts macrophages towards the arterial wall and facilitates their penetration into the subendothelial space through fibronectin (51). Moreover, viral proteins TAT and GP120 induce a rise in the production of endothelin-1 in the vascular endothelium, the most powerful vasoconstrictor known (52,53). Once macrophages have been installed in the subendothelial space, they express the “scavenger” receptor CD36, which will recognize the oxidized lipoproteins (4). At this point, the macrophages start to phagocytize oxidized lipoproteins accumulating cholesterol esters inside and becoming a foam cell. These cells will die by various mechanisms and their cholesterol stores will merge forming the lipid core of the plaque (44). The reverse cholesterol transport mediated by HDL must be able to counteract this situation, but their receptor ABCA1 is inhibited by the viral protein NEF (54). Then, the atheromatous plaque can be eroded resulting in a desquamation of the endothelial cells, which uncovers the matrix and origins the thrombus formation (44). In this point, HIV “per se” may induce the expression of metalloproteases that promote the endothelial desquamation (55,56). The contact of the plaque core with the arterial space induces the platelet aggregation. When platelets are activated they liberate inflammatory cytokines such as RANTES (regulated on activation, normal T-cell expressed and secreted) that reactivate the process initiated by macrophages (44) (Fig2).

In addition, the immune activation and persistent chronic inflammation observed in HIV-infected patients despite ART, are two factors strongly predictive of atherosclerosis (57), and they are associated with the development of non-AIDS events, with an increase in morbidity and mortality and, therefore, with a substantial reduction of patients’ quality of life (28,58–60). Besides, HIV infection induces GM dysbiosis and
ART is not able to completely reverse this situation (27). Only preliminary studies carried out with a small number of patients have showed an improvement in GM composition after treatment with integrase inhibitors (27).

2. CARDIOVASCULAR DISEASE RISK MARKERS IN HIV-INFECTED PATIENTS

Assessment of soluble and cellular proteins together with other approaches such as metagenomic or metabolomic could be used as biomarkers of cardiovascular events in HIV-infected people (61–67). Thus, we have herein classified these potential biomarkers as: (i) biomarkers dependent or partially dependent on microbiota; (ii) biomarkers independent on microbiota.

2.1. Biomarkers dependent on microbiota

2.1.1. Trimethylamine N-oxide

Choline (vitamin B), carnitine and betaine (trimethylglycine) present in diet (mainly in milk, red meat, fish, vegetables and mushrooms) are degraded by the action of trimethylamine lyases present in GM producing trimethylamine (TMA). TMA is subsequently processed by hepatic monooxygenases leading to trimethylamine N-oxide (TMAO) (Fig3). TMAO is normally measured in blood by ultra-high pressure liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS), although there are also other methods developed to measure such metabolite (68). The relation between very high levels of TMAO and the development of future cardiovascular events such as atherosclerosis has been recently recognised in non-HIV patients (69–74). In fact, elevated blood levels of TMAO are associated with worse outcomes in patients with CVD, such as coronary artery disease or heart failure, and with higher mortality (70,74–78). In HIV patients, several studies have also demonstrated the relation between TMAO
and cardiovascular events (14,15,79,80). In one of these studies, high levels of TMAO were significantly associated with an increased risk of plaque incidence in the carotid artery (80). Furthermore, levels of TMAO were associated with higher levels of sCD14 and sCD163, two clusters of differentiation also involved in CVDs, as will be described later (80). Another study demonstrated an independent association between higher TMAO concentrations and higher CVR and between higher TMAO concentrations and multimorbidity (presenting ≥3 comorbidities) in HIV-infected patients (81). In the study from Haismman JM et al. (2017) no differences in TMAO blood levels were observed between naïve and ART-treated HIV patients, although high levels of its precursors, carnitine and betaine, were increased in untreated HIV patients compared to treated ones (82). It will be necessary to ensure if the lack of differences observed in that study between naïve and ART-treated people could be explained by diet. If diet were similar among both groups, it could be suggested that GM is different among both groups in terms of the ability to metabolize TMAO’s precursors. In addition, the lack of differences observed in this study did not discard a significant increased cardiovascular risk in HIV-infected patients and other biomarkers of CVD should also be analysed. In fact, a very recent study has failed to find a strong association between TMAO, gut dysbiosis and inflammation in HIV infection (83). Therefore, the role of this metabolite as a marker of CVD in HIV population deserves further investigation.

2.1.2. Kynurenine/tryptophan ratio

Tryptophan is an essential amino acid (obtained from turkey, chicken, milk, cheese, fish, eggs, tofu, soybeans, sesame and pumpkin seeds, nuts, peanuts and peanut butter) indispensable to promote the liberation of serotonin, involved in the regulation of sleep and desire. Kynurenine is a metabolite resulting from degradation of tryptophan
through the action of GM (84). A study demonstrated that HIV patients (45-50 years old under protease inhibitors) presented a lipid profile that predispose to CVDs and also a higher kynurenine/tryptophan ratio (measured in plasma by UHPLC-MS/MS) than healthy controls (85). However, more studies are needed to validate this ratio as an easy plasma biomarker of CVR in HIV-infected patients.

2.1.3. sCD14 and sCD163

As mentioned before, sCD14 and sCD163 are two clusters of differentiation that act as monocyte activators and inflammation markers as well as indicators of BT. sCD14 (soluble CD14) is secreted by activated monocytes (by proteolytic processing) after the join of lipopolysaccharide (LPS) to the toll-like receptor 4/MD-2 (TLR-4/MD-2) complex mediated by lipopolysaccharide binding protein (LBP) and mCD14 (membrane CD14). sCD14 can join in turn to more LPS and transfer it to mCD14 triggering the activation cascade of a greater number of monocytes (86) (Fig4). On the other hand, CD163, expressed in monocytes, has also two forms, mCD163 (membrane CD163) and sCD163 (soluble CD163). mCD163 is responsible of the removal of plasma hemoglobin through endocytosis of the very high-affinity complex hemoglobin–haptoglobin, thus, preventing the oxidative stress triggered by free hemoglobin through the release of the free iron, bilirubin and carbon monoxide. Moreover, sCD163 acts in the immune system but it is not yet clearly defined how. It is elevated in pathologies such as diabetes, obesity, liver disease and atherosclerosis, all of them characterized by a low-grade inflammation (87).

Regarding HIV-infection, only one study has reported a statistically significant relationship between the levels of sCD14 and sCD163 and new atheromatous plaque formation in HIV patients (88). Obviously, more studies are needed in this regard.
2.1.4. Other biomarkers related to immune activation, inflammation and bacterial translocation

D-dimer is a soluble fibrin degradation product that results from ordered breakdown of thrombin by the fibrinolytic system (89), whereas interleukin-6 (IL-6) is a glycoprotein with pleiotropic effects on inflammation, immune response and hematopoiesis (90). High levels of IL-6 and D-dimer are associated with increased CVR in HIV patients (91,92). Besides, these biomarkers remain high even under ART, which suggest immune activation even with successful suppression of HIV replication (93).

On the other hand, interleukin-1 (IL-1) is an inflammatory cytokine involved in the pathogenesis of multitude inflammatory disorders, including atherosclerosis (94). One study revealed that high levels of IL-1 receptor antagonist (IL-1Ra) in HIV-infected patients were associated with an increased risk of myocardial infarction, supporting the hypothesis that activating IL-1 signaling pathway could be a useful way to reduce CVR in HIV patients. (95).

Finally, when platelets are activated, they secrete other inflammatory cytokines such as RANTES (also known as CCL5), which reactivates the processes initiated by macrophages attracting more leukocytes (44). It has been demonstrated that platelets of HIV patients liberate more RANTES than healthy controls (96,97), although it should be of interest to investigate if this increased RANTES production could be associated with the increased CVR observed in these patients. One study reported that people with coronary atherosclerosis had significantly higher levels of RANTES than controls (98), but no studies have been published in the context of HIV-infection. It is also interesting to point out that CCR5, the receptor of CCL5, acts as a co-receptor of some HIV-1 strains (99) and it has been linked to atherosclerosis (100). Besides, Maraviroc, a CCR5 antagonist used in some HIV-infected patients (those in which HIV-1 has tropism towards
this receptor), has led to statistically significant improvements in several CVR markers (101,102) and inflammation (103).

2.2. Biomarkers independent on microbiota

2.2.1. Endothelin-1

Endothelin-1 is synthesized by the vascular endothelium and presents vasoconstrictive, proinflammatory, profibrosis and promitogenic actions. It has been demonstrated that viral proteins TAT and GP120 are able to induce in the vascular endothelium an increase in the production of this molecule which leads to a higher vasoconstriction (52,53). Specifically, TAT regulates endothelin-1 at the transcriptional level through NF-κβ responsive sites in the promoter (52). The mechanism by which GP120 induces the production of endothelin-1 has not been described yet, but it is also at transcriptional level (104).

Elevated blood levels of endothelin-1 are independently associated with HIV-associated pulmonary arterial hypertension (PAH) maybe through the impairment of pulmonary endothelial function (105). Besides, it has been reported that plasma endothelin-1 levels are higher in HIV patients with PAH than in a non-infected population and also that levels increase with the severity of the PAH (106). The influence of ART on endothelin-1 deserves be further dilucidated.

2.2.2. Markers of oxidative stress

Oxidative stress has been defined as a disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defences, which may lead to tissue injury (107). Besides, the relationship between oxidative stress, ART and
mitochondrial dysfunction has been documented and it is related to alterations in the Krebs cycle and increased levels of ROS (108,109). This suggests that HIV infection and ART may induce oxidative stress (110,111). It has been demonstrated a decrease in the activity of paraoxonase-1 (PON-1), an antioxidant enzyme responsible for inhibiting the lipid peroxidation (112), in HIV-infected patients, which corroborates that HIV infection is accompanied by an increased oxidative stress. However, further studies are required to elucidated the relation between HIV, ART and oxidative stress (113).

The marker of endothelial dysfunction asymmetric dimethylarginine (ADMA) is an inhibitor of nitric oxide synthase (NOS) and it has been proposed as a marker of CVR and oxidative stress in several pathologies. ADMA plasma levels are increased after HIV infection and they seem to be reduced during ART (114). It has been reported that HIV-infected patients with type 2 diabetes show higher ADMA plasma levels than HIV-infected patients without type 2 diabetes (115,116), and taking into account that type 2 diabetes is a CVR factor it is reasonable to assume that it could be a good CVR marker in HIV population.

2.2.3. Lipoprotein-associated phospholipase A2

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), is an enzyme produced by inflammatory cells (mainly macrophages) and responsible for hydrolyzing the oxidated phospholipids present in LDLs (117). It has been suggested that this enzyme could adequately and independently predict the onset of cardiovascular events in the general population (118–120). HIV patients showed higher levels of Lp-PLA2 in comparison with a healthy non-infected population (121,122), and these levels where associated with an elevated CVR in this population (122).
2.2.4. CD4/CD8 ratio

A low CD4/CD8 ratio is considered a hallmark of immunosenescence and is an independent predictor of mortality in the general population (123–125). Specifically, in HIV-infected patients under ART, it has been found a negative correlation between this ratio and immune activation and immunosenescence (126,127). Besides, CD4/CD8 is independently associated with markers of aging and, specifically, to carotid intima-media thickness (cIMT) and vascular stiffness (128). In this context, the analysis of the ICONA cohort showed that CD4/CD8 ratio below 0.30 compared to one above 0.45 was associated to mortality and to have non-AIDS events (129). Finally, another study demonstrated that this ratio was negatively correlated with progression of cIMT (130).

3. MICROBIOTA MODULATION TO REDUCE CARDIOVASCULAR RISK IN HIV PATIENTS: SCIENTIFIC EVIDENCE FROM CLINICAL TRIALS

3.1. Prebiotics

Prebiotics were firstly described in 1995 by Glenn Gibson and Marcel Ruberoid as “a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and thus improves host health” (131).

Eight studies have been published in PubMed concerning prebiotics in HIV-infected patients in the last 10 years. Only 5 are derived from clinical trials and of these, 3 have been discarded because they are related to symbiotics and, therefore, they will be incorporated in the appropriate section of this review. Of the 2 remaining articles, only one (NCT01838915) is registered in ClinicalTrials.gov and, interestingly, one of its objectives was to evaluate the effectiveness of the treatment to modify markers of endothelial dysfunction. However, the results concerning this issue have not been
presented yet. In addition, another clinical trial (NCT04058392) appears in this website and whose aim was to evaluate tolerance and changes in inflammation and microbe composition in stools of HIV-infected people and to assess changes of gut barrier by doing biopsies by colonoscopy. However, it is not completed yet. **Table 2** shows these 2 clinical trials registered in ClinicalTrials.gov, however, we have discussed the results obtained from all 3 clinical trials focused on prebiotics and HIV infection independently of its registration in the website.

Concerning the results published, the administration of prebiotics in HIV patients has proven to be able to modify microbiota composition at several taxonomical levels. However, this influence is only observed in naïve patients (132), possibly due to the fact that time since diagnosis of HIV infection is shorter in naïve patients in comparison with ART-treated patients. Thus, it is possible that the changes at intestinal level in naïve patients induced by the virus are mild and, therefore, can be more easily reversed whereas ART-treated patients could present a more established and stabilised GM. Specifically, naïve HIV patients treated during 6 or 12 weeks with different combinations of prebiotics (short chain galactooligosaccharides/long chain fructooligosaccharides/pectin hydrolysate-derived acidic oligosaccharides/glutamine (scGOS/lcFOS/pAOS/glutamine)) showed significant increases in *Bifidobacterium* genus (from 2.8% to 15.7%, p=0.0007) (133) and in the phyla Firmicutes (included *Faecalibacterium, Catenibacterium, Blautia* and *Eubacterium*) and Actinobacteria (included *Collinsella* and *Corinebacterium*) (132). In contrast, statistically significant decreases in *Clostridium lituseburense/Clostridium histolyctum* (including *Clostridium perfringens* and *Clostridium difficile*) (from 0.016% to 0.002%, p=0.009) (133) and in *Eubacterium rectale/Clostridium coccoides* (p=0.035) have also been demonstrated in these patients (132).
Moreover, the administration of scGOS/lcFOS/pAOS for 12 weeks has also been associated with decreases in BT markers such as sCD14 and LPS in naïve patients (133). However, using a similar mixture of prebiotics (scGOS/lcFOS/glutamine) for 6 weeks no statistically significant differences were observed in these BT markers (132). These discrepancies could be due to the different duration of the intervention (12 weeks vs 6 weeks). Thus, microbiota is rather stable in adulthood and it is necessary longer periods of administration in order to modify it.

It is also interesting to point out that although it has not been observed changes neither in the viral load nor in the number of lymphocytes T CD4 after prebiotic administration, a decrease in the activation of these lymphocytes has been observed after the administration for 12 weeks of scGOS/lcFOS/pAOS (from 0.52% to 0.27 % in naïve patients, p<0.01) (133) or after the intervention with scGOS/lcFOS/glutamine for 6 weeks (132). This could mean that, although the intervention is not able to restore the number of lymphocytes T CD4, it facilitates a reduction of the activation of the immune system, which could be beneficial for these patients, given the persistent chronic inflammation characteristic of HIV infection.

In these two studies, the administration of prebiotics turned out to be safe without being observed modifications in the hepatic or the renal function (132,133). Nevertheless, in terms of tolerability, one of the studies has reported complications (mainly diarrhea), which disappeared 4 weeks after start the intervention (133).

To sum up, the administration of prebiotics in HIV patients was able to modify microbiota composition and to reduce the activation of lymphocytes T CD4, while the effects on markers of inflammation and BT were not clear enough. Besides, there are not studies that analyze if these changes are able to reduce the incidence of co-morbidities in
this population and, specifically, if they are able to reduce CVR. Moreover, the type of compound and the time of administration is a variable to consider when drawing conclusions and making general recommendations. Therefore, it would be of interest to carry out more clinical trials to evaluate the effects of these compounds on CVR factors in HIV-infected patients and, specially, to carry out a follow-up study that could corroborate a significant reduction in cardiovascular events in those subjects with improvements in inflammation and intestinal dysbiosis.

3.2. Probiotics

The internationally endorsed definition of probiotics is “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (134). It has been suggested that the use of probiotics, such as Lactobacillus, Bifidobacterium and Enterococcus that can benefit the intestinal and immune system may be inexpensive and clinically important as coadjutants of ART in order to reduce HIV-related morbidity and mortality (135). The mechanisms by which probiotics may interfere with HIV have been brilliantly summarized by D’Angelo et al., 2017 (136). In essence, probiotics can rebalance microbiota by competition with pathogens, can improve the intestinal barrier reducing BT and, consequently, decreasing systemic inflammation and can restore the mucosal immune function lowering local inflammation (136).

Thirty-five studies have been published in PubMed concerning probiotics in HIV-infected patients in the last 10 years. Only 15 are derived from clinical trials and of these, one has been discarded because it only contains results obtained from symbiotics and, therefore, it will be incorporate in the following section of the review. Another 3 publications have been dismissed because they do not include HIV-infected patients. Besides, we have added two more clinical trials that did not appear in the search carried
out in PubMed but meets the inclusion criteria (137,138) and from the unique meta-analysis and/or systematic review published (139), we have appended one more clinical trial that meets the selection criteria and have not been included previously (140). Of the 17 remaining articles, only 5 appear registered in ClinicalTrials.gov. In addition, in this website another 11 clinical trials different from the abovementioned appeared. Thus, Table 3 shows all clinical trials registered in ClinicalTrials.gov although the discussion of all 25 clinical trials focused on probiotics and HIV infection has been included in this section.

The administration of probiotics in HIV infected patients has proved to be able to modify microbiota composition both in naïve patients and in ART-treated patients. Specifically, intervention of ART-treated patients with different combinations of probiotics was associated with an increase of the relative abundance of Actinobacteria and Firmicutes phyla [administration of 250 ml/day of fermented skimmed milk supplemented with Lactobacillus rhamnosus GG (10^8 CFU/ml), Bifidobacterium animalis subsp. lactis B-12 (10^8 CFU/ml) and Lactobacillus acidophilus La-5 (10^7 CFU/ml); 8 weeks] (141), and also with an increase of Bifidobacteria spp [administration of Visbiome®; twice a day; 24 weeks] (142). A statistically significant increase in the abundance of Megamonas and Desulfovibrionales levels after the administration for 12 weeks of capsules with 56.5 mg living Saccharomyces boulardii have also been observed (143). In contrast, a statistically significant reduction of Bacteroidetes phylum and some species of Clostridiales and Catenibacterium have also been demonstrated after the administration of 250 ml/day of fermented skimmed milk supplemented with Lactobacillus rhamnosus GG (10^8 CFU/ml), Bifidobacterium animalis subsp. lactis B-12 (10^8 CFU/ml) and Lactobacillus acidophilus La-5 (10^7 CFU/ml) for 8 weeks (141) and after the administration of capsules with 56.5 mg living Saccharomyces boulardii,
respectively (143). In a study carried out in naïve patients, a decrease in the total load of bacteria in stools with respect to the placebo group and an increase of the \textit{Bifidobacterium} spp. concentration along with a decrease of the \textit{Clostridium} spp. concentration was demonstrated after daily administration of \textit{Lactobacillus rhamnosus} HN001 plus \textit{Bifidobacterium lactis} Bi-07 (10^9 CFU/ml) for 16 weeks (144). Finally, in a study with both naïve and ART-treated patients, a reduction of the orders Enterobacteriales (p=0.018) and Erysipelotrichales (p=0.037), entirely driven by a reduction of the Enterobacteriaceae and Erysipelotrichaceae families were observed along with an increase in an uncultured genus from the Lachnospiraceae family (p=0.015) and \textit{Ruminiclostridium} (P=0.023) from the Ruminicoccaceae family [administration of 2 capsules daily of \textit{Lactobacillus rhamnosus} GG (10^{10} CFU); 8 weeks] (145).

Concerning inflammation, the administration twice a day for 48 weeks of 1g packet (from now indicated as packet A) containing \textit{Streptococcus salivarius} ssp. \textit{thermophilus} (at least 2.04x10^{14} CFU), Bifidobacteria represented by \textit{B. breve}, \textit{B. infantis} and \textit{B. longum} (at least 9.3x10^{13}), \textit{Lactobacillus acidophilus} (at least 2 billion CFU), \textit{Lactobacillus plantarum} (at least 2.20x10^8 CFU), \textit{Lactobacillus casei} (at least 2.20x10^8 CFU), \textit{Lactobacillus delbrueckii} ssp. \textit{bulgaricus} (at least 3x10^8 CFU) and \textit{Streptococcus faecium} (at least 3x10^7 CFU) was not able to reduce D-dimer levels (146). However, the administration of 250 ml/day of fermented skimmed milk supplemented with \textit{Lactobacillus rhamnosus} GG (10^8 CFU/ml), \textit{Bifidobacterium animalis} subsp. \textit{lactis} B-12 (10^8 CFU/ml) and \textit{Lactobacillus acidophilus} La-5 (10^7 CFU/ml) for 8 weeks was able to reduce both the levels of D-dimer (p=0.03) and IL-6 (p=0.06) compared to the placebo group (141). In addition, the administration for 12 weeks of \textit{Saccharomyces boulardii} has also been able to reduce IL-6 levels respect to the placebo group (137). These discrepancies could be due to the different combinations used and, therefore, it makes
difficult to conclude the positive effects of probiotics on inflammation or at least on these parameters measured (D-dimer and/or IL-6). In relation to the effects on BT, different combinations of probiotics (capsules with 56.5 mg living *Saccharomyces boulardii*, packet A and *Saccharomyces boulardii*) have been able to decrease LBP levels with respect to the placebo group (137,143,146). However, no effects in sCD14 or sCD163 levels have been observed (141,143,145,146) despite the fact that sCD14 has been suggested to be a more relevant biomarker of disease progression as it reflects the host response to products of BT (147). These results make very difficult to confirm the beneficial effects of these probiotics on BT.

On the other hand, it has been observed an increase in the number of lymphocytes T CD4 in ART-treated patients after the administration of *L. rhamnosus* GR-1 and *L. reuteri* RC-14 for 25 weeks (148). Moreover, it has also been observed an increase in the percentage of lymphocytes T CD4 in the probiotic group after the administration of packet A (146). The administration of *Bacillus coagulans* GBI-30, 6086 (Ganeden BC30; 2x1012 CFU) [once daily; 90 days] was also associated with a significant increase in the percentage of lymphocytes T CD4 compared to placebo (+2.8% vs. -1.8%, p=0.018), although their concentrations were generally unchanged inside each group (140). Nonetheless, no increases were observed after the administration of 125 ml yoghurt fortified with *L. rhamnosus* GR-1 (1.23x10⁹ CFU/ml) [once a day; 4 weeks], possibly due to the lower duration of the intervention (149). It is also interesting the decrease observed in the activation markers CD38 and HLA-DR after the administration of packet A (146) and after the administration of Visbiome® for 24 weeks (150).

In all these studies, the administration of probiotics turned to be safe without side effects or modifications in hepatic or renal functions (138,140,146,148–152).
In summary, to date, we have some scientific evidence showing that the administration of probiotics in HIV patients is able to modify microbiota composition, increase the number of lymphocytes T CD4, decrease their activation and reduce LBP levels. There are more studies than in the case of prebiotics but, in general terms, these studies do not address the potential effects of these probiotics on CVR in HIV population. Moreover, it is necessary to assess if the changes observed in markers of inflammation and BT after the ingestion of probiotics could lead to improvements in the incidence of co-morbidities and, specifically, CVR, in this population. In addition, the huge variability in the type of compound used, the dose and the time of administration makes it impossible to obtain verified and confirmed conclusions. Therefore, the first step would be to make a good description using large cohorts of the bacterial species that are decreased in HIV-infected patients. Secondly, these depleted species would be good candidates to ingest as probiotics to restore GM, but they should pass the requirements imposed by FAO and WHO to be used with any doubt of their safety. And, finally, the effects of these probiotics should be assessed in HIV-infected patients taking into account markers of inflammation, BT but also CVR, among others.

3.3. Symbiotics

The term symbiotics was introduced by Gibson and Roberfroid in 1995 to describe a combination of synergistically acting prebiotics and probiotics (131).

Five studies have been published in PubMed concerning symbiotics in HIV-infected patients in the last 10 years. Only 4 were derived from clinical trials. Of the 4 remaining articles, 3 appear registered in ClinicalTrials.gov. In addition, 2 more clinical trials were included in this website. The first one (NCT03568812) is still recruiting patients and its objective was to assess changes in immunity and in inflammation and BT
markers. The objective of the second trial (NCT03542786), also in a recruiting state, was to evaluate inflammation and premature aging. It will be interesting to analyze the results of these clinical trials as soon as they are concluded. Table 4 shows clinical trials concerning symbiotics registered in ClinicalTrials.gov. Again, the discussion of all 6 clinical trials has been included in this review.

The administration of symbiotics in HIV patients has proved to be able to modify GM composition. Specifically, the administration for 16 weeks of 10 g of agavins from Agave tequilana plus Lactobacillus rhamnosus HN001 and Bifidobacterium lactis Bi-07 (10^9 CFU/ml) in naïve patients induced a statistically significant decrease in total load of bacteria in stool with respect to the placebo group (144). Similarly, in another study carried out in ART-treated patients, an increase in the levels of L. plantarum and P. pentosaceus with respect to the placebo group was detected after the administration of Synbiotic 2000® during 4 weeks (153). However, the administration of PMT25431 during 48 weeks in naïve patients who initiated ART was not accompanied by significant changes in gut microbiota (154).

Concerning inflammation, a study with naïve patients demonstrated a statistically significant decrease in IL-6 levels with respect to the beginning of the intervention after the administration of 10 g of agavins from Agave tequilana plus Lactobacillus rhamnosus HN001 and Bifidobacterium lactis Bi-07 (10^9 CFU/ml) (144). However, the administration of PMT25431 during 48 weeks in naïve patients who initiate ART was not able to induce additional changes in IL-6 levels (154). Moreover, no effects were observed in the plasma levels of TNF-α, IL-1β, IL-10, sCD14 or sCD163 in naïve HIV-infected patients after the administration of 10 g of agavins from Agave tequilana plus Lactobacillus rhamnosus HN001 and Bifidobacterium lactis Bi-07 (10^9 CFU/ml) (144).
No actions of PMT25341 administration for 48 weeks were observed in naïve patients who initiated ART (154), and no effects were either observed in ART-treated patients after the administration of Synbiotic 2000® during 4 weeks (153).

An increase in the levels of lymphocytes T CD4 with respect to the beginning of the treatment was observed in naïve HIV-infected patients after the administration of 10 g of agavins (144). However, no effects were observed after 4 weeks of administration of Synbiotic 2000® in ART-treated patients (153). These discrepancies could be due to the different length of intervention, the different product used and the fact that in the second study, subjects were ART-treated and their GM could be more established, as previously mentioned. Finally, the administration of PMT25341® for 48 weeks in naïve HIV-infected patients who initiate ART did not induce additional changes to those exerted by ART at both levels and activation of T CD4 lymphocytes (154).

In all these studies, the administration of symbiotics was safe without side effects (144,153,155). Besides, the administration of LACTOFOS© twice daily for 30 weeks in naïve patients was able to significantly reduce diarrhea (reduction of 21.8% in incidents), nausea and/or vomits (reduction of 28.8% in incidents), constipation (reduction of 13.2% in incidents) and dyspepsia (reduction of 24.5% in incidents) (155).

In general terms, the results showed that the administration of symbiotics in HIV patients was able to modify microbiota composition, while the effects on the number of lymphocytes T CD4 and the markers of inflammation and BT were not as clear as in the case of probiotics, which results interesting considering that symbiotics are a mixture of probiotics and prebiotics. However, these discrepancies could be a consequence of the different probiotic used or/and the different length of administration. Similarly as what was observed in prebiotics and probiotics, there are not studies focused on the long-term
consequences of these changes. Moreover, there is a huge variability in the type of compound, the dose and the length of administration, so it is impossible to make conclusions and general recommendations.

3.4. Fecal transplantation

FT is the transfer of stools from a healthy donor into a patient with a disease characterized by a significant altered microbiome. Its objective is to restore the microbiota and, therefore, to treat the disease (156). FT is not new, in fact, there are reports of its use in ancient China for various purposes (157). It was firstly described as a treatment for pseudomembranous colitis in the 1950s (158) and in the recent years it has gained acceptance as a safe and effective treatment for recurrent *Clostridioides difficile* infection (CDI) associated diarrhea (159–163).

It has been observed that HIV patients treated for CDI by FT do not show any adverse events (164). However, in the same study, 14% of the inflammatory bowel disease (IBD)-patients experienced a disease flare requiring hospitalization in some cases (164). Therefore, FT involves an uncontrollable risk, particularly in immunocompromised patients if donor samples are not checked (165–167). In this context, the use of fecal filtrates could be a great alternative (168). Thus, despite all the advances in this field, the optimal protocol for FT is unknown and more well-designed studies and clinical trials are required because controversy issues are arising nowadays (169).

To our knowledge, 4 clinical trials have been registered up to date in ClinicalTrials.gov, while the results of these clinical trials have not been published yet nor uploaded to PubMed. Thus, it will be interesting to analyze the results of these clinical
trials in the future. Table 5 shows clinical trials concerning FT registered in ClinicalTrials.gov.
DISCUSSION

Our review has revealed that among all the GM modulatory strategies analysed (prebiotics, probiotics, symbiotics and FT), probiotics emerge as the most beneficial therapies in HIV patients to improve their immune and inflammatory state. However, there are very few studies focused on their effects on specific CVR markers in HIV patients and focused on the long-term consequences of these effects on inflammation. In fact, follow-up studies to corroborate if the effects of probiotics on BT and inflammation lead to statistically significant reductions in cardiovascular events in those subjects with improvements in inflammation, intestinal dysbiosis and CVR factors are missing. In addition, a huge variability in the type of compound, the dose and the length of administration has been observed among the trials, although it seems that the most positive effects have been observed in long-term duration of the intervention. This could suggest that due to the fact that microbiota is quite stable in adulthood, a duration between 12 and 40 weeks is required to be able to modify/modulate it.
CONCLUSIONS

To sum up, HIV-infected patients have significant increased rates of cardiovascular events even after controlling for traditional CVR factors and this significantly affects their quality of life and represents a significant increase in healthcare costs. The usage of probiotics or other GM modulatory strategies along with the standard of care (i.e., ART) could be a good strategy to modify CVR factors in this population. However, more prospective controlled clinical trials with larger number of patients and with standardized dose, and duration of therapies are needed. Patients´ follow-up will be also required to confirm the results.
LIST OF ABBREVIATIONS

ADMA: asymmetric dimethylarginine

AIDS: acquired immune deficiency syndrome

AMI: acute myocardial infarction

ART: antiretroviral therapy

BT: bacterial translocation

CDI: Clostridioides difficile infection

CFU: colony forming unit

cIMT: carotid intima-media thickness

CVD: cardiovascular disease

CVR: cardiovascular risk

FAO: Food and Agriculture Organization

FDA: Food and Drug Administration

FT: fecal transplantation

GALT: gut-associated lymphoid tissue

GM: gut microbiota

HIV: human immunodeficiency virus
HPV: human papillomavirus

IBD: inflammatory bowel disease

IBS: irritable bowel syndrome

IL-1: interleukin-1

IL-1Ra: interleukin-1 receptor antagonist

IL-6: interleukin-6

INR: immunological non-responder

IR: immunological responder

LBP: lipopolysaccharide binding protein

lcFOS: long chain fructooligosaccharides

Lp-PLA2: lipoprotein-associated phospholipase A2

LPS: lipopolysaccharide

mCD14: membrane CD14

mCD163: membrane CD163

MCP-1: monocyte chemoattractant protein

MDROs: multi-drug-resistant organisms

MHC: major histocompatibility complex
MSM: men who have sex with men

NAFLD: non-alcoholic fatty liver disease

NOS: nitric oxide synthase

PAF-AH: platelet-activating factor acetylhydrolase

PAH: pulmonary arterial hypertension

pAOS: pectin hydrolysate-derived acidic oligosaccharides

PON-1: paraoxonase-1

RANTES: regulated on activation, normal T-cell expressed and secreted

sCD14: soluble CD14

sCD163: soluble CD163

scGOS: short chain galactooligosaccharides

TCRs: T-cell receptors

TLR-4: toll-like receptor 4

TMA: trimethylamine

TMAO: trimethylamine N-oxide

UHPLC-MS/MS: ultra-high pressure liquid chromatography coupled to tandem mass spectrometry
VCAM-1: vascular cell adhesion molecule-1

WHO: World Health Organization
DECLARATIONS

Ethics approval and consent to participate: not applicable.

Consent for publication: not applicable

Availability of data and materials: all data generated or analysed during this study are included in this published article.

Competing interests: the authors declare that they have no competing interests.

Funding: Pablo Villoslada-Blanco was supported by a predoctoral grant from Consejería de Desarrollo Económico e Innovación (Government of La Rioja).

Author’s contributions: PPM and JAO conceived the study concept. PVB conducted the literature research and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Consejería de Desarrollo Económico e Innovación and Fundación Rioja Salud (Government of La Rioja).
REFERENCES

1. Deeks SG, Lewin SR, Havlir D V. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1523–33.

2. Desai SN, Landay AL. HIV and aging: Role of the microbiome. Curr Opin HIV AIDS. 2018;13(1):22–7.

3. Desai SN, Landay AL. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7(1):4–10.

4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12.

5. Smith RL, de Boer R, Brul S, Budovskaya Y V, van der Spek H. Premature and accelerated aging: HIV or HAART? Front Genet. 2013;3:328.

6. Negredo E, Back D, Blanco JR, Blanco J, Erlandson KM, Garolera M, et al. Aging in HIV-Infected Subjects: A New Scenario and a New View. Biomed Res Int. 2017;2017:58972.

7. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. Journals Gerontol Ser A Biol Sci Med Sci. 2007;62(11):1279–86.

8. Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. Curr Opin Immunol. 2012;24(4):501–6.

9. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIV-infected persons
continue to lose kidney function despite successful antiretroviral therapy. AIDS. 2009;23(16):2143–9.

10. Alejos B, Hernando V, López-Aldeguer J, Segura F, Antonio Oteo J, Rubio R, et al. Overall and cause-specific mortality in HIV-positive subjects compared to the general population. J Int AIDS Soc. 2014;17(4 Suppl 3):19711.

11. Freiberg MS, Chang CCH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–22.

12. Paisible A-L, Chang J, Armah K, Goetz MB, Butt AA, Rodriguez-Barradas MC, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015;68(2):209–16.

13. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study. Clin Infect Dis. 2007;44(12):1625–31.

14. Haissman JM, Knudsen A, Hoel H, Kjær A, Kristoffersen US, Berge RK, et al. Microbiota-Dependent Marker TMAO Is Elevated in Silent Ischemia but Is Not Associated with First-Time Myocardial Infarction in HIV Infection. J Acquir Immune Defic Syndr. 2016;71(2):130–6.

15. Sriniivasa S, Fitch K V., Lo J, Kadar H, Knight R, Wong K, et al. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS. 2015;29(4):443–52.

16. Al-Kindi SG, Kim CH, Morris SR, Freeman ML, Funderburg NT, Rodriguez B,
et al. Elevated red cell distribution width identifies elevated cardiovascular disease risk in patients with HIV infection. J Acquir Immune Defic Syndr. 2017;74(3):298–302.

17. Haissman JM, Haugaard AK, Knudsen A, Kristoffersen US, Seljeflot I, Pedersen KK, et al. Marker of endothelial dysfunction asymmetric dimethylarginine is elevated in HIV infection but not associated with subclinical atherosclerosis. J Acquir Immune Defic Syndr. 2016;73(5):507–13.

18. Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, D’Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: A review. BMC Infect Dis. 2017;17(1):551.

19. Jorth P, Turner KH, Gumus P, Nizam N, Buduneli N, Whiteley M. Metatranscriptomics of the human oral microbiome during health and disease. MBio. 2014;5(2):e01012–4.

20. Lynch S V., Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016;375(24):2369–79.

21. Fujimura KE, Slusher NA, Cabana MD, Lynch S V. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther. 2010;8(4):435–54.

22. Villanueva-Millán MJ, Pérez-Mature P, Oteo JA. Gut microbiota: a key player in health and disease. A review focused on obesity. J Physiol Biochem. 2015;71(3):509–25.

23. Vandeputte D, Kathagen G, D’Hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J, et al. Quantitative microbiome profiling links gut community variation to
microbial load. Nature. 2017;551(7681):507–11.

24. Yarza P, Yilmaz P, Pruesse E, Glöckner FO, Ludwig W, Schleifer K-H, et al. Uniting the classification of cultured and uncultured bacteria and archaea using 16S rRNA gene sequences. Nat Rev Microbiol. 2014;12(9):635–45.

25. Waldman AJ, Balskus EP. The Human Microbiota, Infectious Disease, and Global Health: Challenges and Opportunities. ACS Infect Dis. 2018;4(1):14–26.

26. Zhang Y, Lun CY, Tsui SKW. Metagenomics: A new way to illustrate the crosstalk between infectious diseases and host microbiome. Vol. 16, International Journal of Molecular Sciences. 2015. p. 26263–79.

27. Villanueva-Millán MJ, Pérez-Matute P, Recio-Fernández E, Rosales JML, Oteo JA. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients. J Int AIDS Soc. 2017;20(1):21526.

28. Zevin AS, McKinnon L, Burgener A, Klatt NR. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2016;11(2):182–90.

29. Ebrahimzadeh LH, Ghotaslou R, Samadi KH, Feizabadi MM, Moaddab SY, Farajnia S, et al. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2020;39(4):613–27.

30. Barengolts E. Gut microbiota, prebiotics, probiotics, and synbiotics in management of obesity and prediabetes: Review of randomized controlled trials.
31. Markowiak P, Ślizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021.

32. El-Far M, Tremblay CL. Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease. Curr Opin HIV AIDS. 2018;13(1):38–44.

33. Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr Clin Res Rev. 2019;13(5):2917–22.

34. Sivamaruthi BS, Kesika P, Suganthi N, Chaiyasut C. A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements. Biomed Res Int. 2019 May 9;2019:1–20.

35. Pérez-Matute P, Pichel JG, Iñiguez M, Recio-Fernández E, Pérez-Martínez L, Torrens R, et al. Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity. Antivir Ther. 2017;22(2):163–8.

36. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072–84.

37. Juszczuk K, Grudlewska K, Mikucka A, Gospodarek E. Fecal microbiota transplantation - methods of treatment of recurrent Clostridium difficile infections and other diseases. Postepy Hig Med Dosw (Online). 2017;71(0):220–
6.

38. Food and Agriculture Organization WHO, (FAO/WHO). Report of a Joint FAO/WHO Expert Consultation on Evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO Rep. 2001;10(1).

39. ScienceNews. To regulate fecal transplants, FDA has to first answer a serious question: What is poop? [Internet]. Available from: https://www.sciencenews.org/blog/scicurious/fecal-transplants-regulation

40. U.S. Food & Drug Administration (FDA). Fecal Microbiota for Transplantation: Safety Communication- Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms [Internet]. Available from: https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-communication-risk-serious-adverse-reactions-due

41. Varoni EM, Lodi G, Iriti M. Efficacy behind activity–phytotherapeutics are not different from pharmaceuticals. Pharm Biol. 2015;53(3):404–6.

42. ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/home

43. Micheletti RG, Fishbein G a, Fishbein MC, Singer EJ, Weiss RE, Jeffries R a, et al. Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study. Cardiovasc Pathol. 2009;18(1):28–36.

44. Alonso-Villaverde Lozano C. Fisiopatología de la enfermedad cardiovascular en pacientes con VIH. Enferm Infecc Microbiol Clin. 2009;27(SUPPL. 1):33–9.
45. Wilson P. Overview of established risk factors for cardiovascular disease. UptoDate. 2019;13.

46. Birdsall HH, Trial J, Lin HJ, Green DM, Sorrentino GW, Siwak EB, et al. Transendothelial migration of lymphocytes from HIV-1-infected donors: a mechanism for extravascular dissemination of HIV-1. J Immunol. 1997;158(12):5968–77.

47. Arese M, Ferrandi C, Primo L, Camussi G, Bussolino F. HIV-1 Tat Protein Stimulates In Vivo Vascular Permeability and Lymphomononuclear Cell Recruitment. J Immunol. 2001;166(2):1380–8.

48. Choi J, Walker J, Talbert-Slagle K, Wright P, Pober JS, Alexander L. Endothelial Cells Promote Human Immunodeficiency Virus Replication in Nondividing Memory T Cells via Nef-, Vpr-, and T-Cell Receptor-Dependent Activation of NFAT. J Virol. 2005;79(17):11194–204.

49. Park IW, Wang JF, Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood. 2001;97(2):352–8.

50. Liu K, Chi DS, Li C, Hall HK, Milhorn DM, Krishnaswamy G. HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery endothelial cells and its signaling. Am J Physiol Cell Mol Physiol. 2005;289(2):L252–60.

51. ABirdsall HH, Porter WJ, Green DM, Rubio J, Trial J, Rossen RD. Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes. J
52. Chauhan A, Hahn S, Gartner S, Pardo CA, Netesan SK, McArthur J, et al. Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins. FASEB J. 2007;21(3):777–89.

53. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun. 2005;333(4):1107–15.

54. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4(11):1970–83.

55. Yano M, Nakamuta S, Shiota M, Endo H, Kido H. Gatekeeper role of 14-3-3 protein in HIV-1 gp120-mediated apoptosis of human endothelial cells by inactivation of Bad. AIDS. 2007;21(8):911–20.

56. Borgne-Sanchez A, Dupont S, Langonné A, Baux L, Lecoeur H, Chauvier D, et al. Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of αVβ3-expressing endothelial cells. Cell Death Differ. 2007;14(3):422–35.

57. Trøseid M, Manner IW, Pedersen KK, Haissman JM, Kvale D, Nielsen SD. Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retroviruses. 2014;30(6):514–22.

58. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013;26(1):2–18.
59. Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther. 2013;10(1):29.

60. Lozupone CA, Stombaugh JJ, Gordon JJ, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220.

61. Rasmussen LH, Knudsen A, Katzenstein TL, Gerstoft J, Obel N, Jørgensen NR, et al. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: A nested case-control study. HIV Med. 2016;17(5):350–7.

62. Secemsky EA, Scherzer R, Nitta E, Wu AHB, Lange DC, Deeks SG, et al. Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC Hear Fail. 2015;3(8):591–9.

63. Vos AG, Hulzebosch A, Grobbee DE, Barth RE, Klipstein-Grobusch K. Association between immune markers and surrogate markers of cardiovascular disease in HIV positive patients: A systematic review. PLoS One. 2017;12(1):e0169986.

64. Vos AG, Idris NS, Barth RE, Klipstein-Grobusch K, Grobbee DE. Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic Review. PLoS One. 2016;11(1):e0147484.

65. Dirajlal-Fargo S, Sattar A, Kulkarni M, Funderburg N, McComsey GA. Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection. HIV Clin
Trials. 2017;18(4):156–63.

66. Knudsen A, Katzenstein TL, Benfield T, Jørgensen NR, Kronborg G, Gerstoft J, et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. AIDS. 2014;28(8):1171–9.

67. Bellasi A, Raggi P, Rossi R, Rochira V, Stentarelli C, Zona S, et al. Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. Atherosclerosis. 2014;237(2):618–22.

68. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine n-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398.

69. Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. 2016;27(1):305–13.

70. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. N Engl J Med. 2013;368(17):1575–84.

71. Trøseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277(6):717–26.

72. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature.
73. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.

74. Tang WHW, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015;21(2):91–6.

75. Wang Z, Tang WHW, Buffa JA, Fu X, Britt EB, Koeth RA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35(14):904–10.

76. Suzuki T, Heaney LM, Bhandari SS, Jones DJL, Ng LL. Trimethylamine N-oxide and prognosis in acute heart failure. Heart. 2016;102(11):841–8.

77. Fu Q, Zhao M, Wang D, Hu H, Guo C, Chen W, et al. Coronary Plaque Characterization Assessed by Optical Coherence Tomography and Plasma Trimethylamine-N-oxide Levels in Patients With Coronary Artery Disease. Am J Cardiol. 2016;118(9):1311–5.

78. Suzuki T, Heaney LM, Jones DJL, Ng LL. Trimethylamine N-oxide and risk stratification after acute myocardial infarction. Clin Chem. 2017;63(1):420–8.

79. Elliott Miller P, Haberlen SA, Brown TT, Margolick JB, DiDonato JA, Hazen SL, et al. Intestinal microbiota-produced trimethylamine-N-oxide and its association with coronary stenosis and HIV serostatus. J Acquir Immune Defic
80. Shan Z, Clish CB, Hua S, Scott JM, Hanna DB, Burk RD, et al. Gut microbial-related choline metabolite trimethylamine-N-oxide is associated with progression of carotid artery atherosclerosis in HIV infection. J Infect Dis. 2018;218(9):1474–9.

81. Montrucchio C, De Nicolò A, D’Ettorre G, D’Ascenzo F, Lazzaro A, Tettoni M, et al. Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotics Supplementation. Int J Antimicrob Agents. 2020;55(4):105908.

82. Haissman JM, Haugaard AK, Ostrowski SR, Berge RK, Hov JR, Trøseid M, et al. Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection. BMC Infect Dis. 2017;17(1):445.

83. Missailidis C, Neogi U, Stenvinkel P, Trøseid M, Nowak P, Bergman P. The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages. AIDS. 2018;32(12):1589–98.

84. Więdlocha M, Marcinowicz P, Janoska-Jaździk M, Szulc A. Gut microbiota, kynurenine pathway and mental disorders–Review. Prog Neuropsychopharmacology Biol Psychiatry. 2020;110145.

85. Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation,
microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis. 2013;13(1):2013.

86. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005;11(4):225–9.

87. Thomsen HH, Møller HJ, Trolle C, Groth KA, Skakkebæk A, Bojesen A, et al. The macrophage low-grade inflammation marker sCD163 is modulated by exogenous sex steroids. Endocr Connect. 2013;2(4):216–24.

88. Hanna DB, Lin J, Post WS, Hodis HN, Xue X, Anastos K, et al. Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men. J Infect Dis. 2017;215(9):1352–61.

89. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411–20.

90. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.

91. Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD. Severity of cardiovascular disease outcomes among patients with hiv is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014;3(3):e000844.

92. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e4445.
93. Neuhaus J, Jacobs, Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al.Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. J Infect Dis. 2010;201(12):1788–95.

94. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27.

95. Hoel H, Ueland T, Knudsen A, Kjær A, Michelsen AE, Sagen EL, et al. Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals. J Infect Dis. 2019;221(4):506–9.

96. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009;50(Supplement):S352–7.

97. Holme PA, Müller F, Solum NO, Brosstad F, Frøland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 1998;12(1):79–90.

98. Podolec J, Kopec G, Niewiara L, Komar M, Guzik B, Bartus K, et al. Chemokine RANTES is increased at early stages of coronary artery disease. J Physiol Pharmacol. 2016;67(2):321–8.

99. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (80- ). 2013;341(6152):1387–90.

100. Maguire JJ, Jones KL, Kuc RE, Clarke MCH, Bennett MR, Davenport AP. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro. Cardiovasc Res. 2014;101(3):513–21.
101. Francisci D, Pirro M, Schiaroli E, Mannarino MR, Cipriani S, Bianconi V, et al. Maraviroc intensification modulates atherosclerotic progression in HIV-suppressed patients at high cardiovascular risk. A randomized, crossover pilot study. Open Forum Infect Dis. 2019;6(4):1–7.

102. Piconi S, Pocaterra D, Rainone V, Cossu M, Masetti M, Rizzardini G, et al. Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients. Sci Rep. 2016;6:28853.

103. Afonso P, Auclair M, Caron-Debarle M, Capeau J. Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence. Antivir Ther. 2017;22(8):645–57.

104. Didier N, Banks WA, Créminon C, Dereuddre-Bosquet N, Mabondzo A. HIV-I-induced production of endothelin-I in an in vitro model of the human blood-brain barrier. Neuroreport. 2002;13(9):1179–83.

105. Parikh R V., Ma Y, Scherzer R, Heringer AS, Macgregor JS, Martin JN, et al. Endothelin-1 predicts hemodynamically assessed pulmonary arterial hypertension in HIV infection. PLoS One. 2016;11(1):e0146355.

106. Feijoo MQ, Toro R, De La Torre MLV, Lennie V, Arce C, Moreno V, et al. Relationship between endothelin-1 levels and pulmonary arterial hypertension in HIV-infected patients. AIDS. 2014;28(18):2693–9.

107. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 1994;344(8924):721–4.

108. Sundaram M, Saghayam S, Priya B, Venkatesh KK, Balakrishnan P, Shankar
EM, et al. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis. 2008;12(6):e61-66.

109. Masiá M, Padilla S, Fernández M, Rodríguez C, Moreno A, Oteo JA, et al. Oxidative stress predicts All-Cause mortality in HIV-Infected patients. PLoS One. 2016;11(4):e0153456.

110. Sharma B. Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy. Curr HIV Res. 2014;12(1):13–21.

111. Hulgan T, Morrow J, D’Aquila RT, Raffanti S, Morgan M, Rebeiro P, et al. Oxidant Stress Is Increased during Treatment of Human Immunodeficiency Virus Infection. Clin Infect Dis. 2003;37(12):1711–7.

112. Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis. 2007;194(1):175–81.

113. Miranda Pérez AA, Gutiérrez Pérez ME, Urraza Robledo AI, Delgadillo Guzmán D, Ruiz Flores P, López Márquez FC. Klotho-HIV and Oxidative Stress: The Role of Klotho in Cardiovascular Disease Under HIV Infection-A Review. DNA Cell Biol. 2020;39(9):1478–85.

114. P. Pérez-Matute, L. Pérez-Martínez, E. Recio-Fernández, V. Ibarra, L. Metola, M. Sanz, J.R. Blanco JAO. ¿Es el ADMA un buen biomarcador de lipodistrofia en la población VIH? Enferm Infect Microbiol Clin. 2013;31(Especial Congreso 1):159–60.
115. Hoel H, Hove-Skovsgaard M, Hov JR, Gaardbo JC, Holm K, Kummen M, et al. Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction. Sci Rep. 2018;8(1):6725.

116. Hove-Skovsgaard M, Gaardbo JC, Kolte L, Winding K, Seljeflot I, Svardal A, et al. HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation. BMC Infect Dis. 2017;17(1):234.

117. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: A new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7(5):511–7.

118. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(6):527–32.

119. Oei HHS, Van Der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation. 2005;111(5):570–5.

120. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study. Atherosclerosis. 2010;209(2):528–32.

121. Díaz-Pollán B, Estrada V, Fuentes-Ferrer M, Gómez-Garré D, San Román-Montero J. Lp-PLA2 levels in HIV-infected patients. J Int AIDS Soc. 2014;17(4
122. Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak JF, Karas RH, et al.
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory
marker, in HIV-infected patients. Clin Infect Dis. 2014;58(6):893–900.

123. Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Löfgren S, et al. The
immune risk phenotype is associated with IL-6 in the terminal decline stage:
Findings from the Swedish NONA immune longitudinal study of very late life
functioning. Mech Ageing Dev. 2006;127(8):695–704.

124. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, et al. An
immune risk phenotype, cognitive impairment, and survival in very late life:
Impact of allostatic load in Swedish octogenarian and nonagenarian humans.
Journals Gerontol - Ser A Biol Sci Med Sci. 2005;60(5):556–65.

125. Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, et al.
Longitudinal Studies of Clonally Expanded CD8 T Cells Reveal a Repertoire
Shrinkage Predicting Mortality and an Increased Number of Dysfunctional
Cytomegalovirus-Specific T Cells in the Very Elderly. J Immunol.
2006;176(4):2645–53.

126. Sainz T, Serrano-Villar S, Díaz L, Tome MIG, Gurbindo MD, De José MI, et al.
The CD4/CD8 ratio as a marker T-cell activation, senescence and
activation/exhaustion in treated HIV-infected children and young adults. AIDS.
2013;27(9):1513–6.

127. Serrano-Villar S, Pérez-Elías MJ, Dronda F, Casado JL, Moreno A, Royuela A,
et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One. 2014;9(1):e85798.

128. Serrano-Villar S, Moreno S, Fuentes-Ferrer M, Sánchez-Marcos C, Ávila M, Sainz T, et al. The CD4: CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med. 2014;15(1):40–9.

129. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastrì E, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study. Lancet HIV. 2015;2(3):e98-106.

130. Morell EB, Cabeza JS, Muñoz Á, Marín I, Masiá M, Gutiérrez F, et al. The CD4/CD8 Ratio is Inversely Associated with Carotid Intima-Media Thickness Progression in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Treatment. AIDS Res Hum Retroviruses. 2016;32(7):648–53.

131. Gibson GR, Roberfroid MB. Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J Nutr. 1995;125(6):1401–12.

132. Serrano-Villar S, Vázquez-Castellanos JF, Vallejo A, Latorre A, Sainz T, Ferrando-Martínez S, et al. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. Mucosal Immunol. 2017;10(5):1279–93.

133. Gori A, Rizzardini G, Van’T Land B, Amor KB, Van Schaik J, Torti C, et al.
Specific prebiotics modulate gut microbiota and immune activation in HAART-naïve HIV-infected adults: Results of the “cOPA” pilot randomized trial. Mucosal Immunol. 2011;4(5):554–63.

134. Sanders ME. Probiotics: Definition, Sources, Selection, and Uses. Clin Infect Dis. 2008;46(s2):S58–61.

135. Hummelen R, Vos AP, Van’T Land B, Van Norren K, Reid G. Altered host-microbe interaction in HIV: A target for intervention with pro- and prebiotics. Int Rev Immunol. 2010;29(5):485–513.

136. D’Angelo C, Reale M, Costantini E. Microbiota and probiotics in health and HIV infection. Nutrients. 2017;9(6):615.

137. Villar-García J, Hernández JJ, Güerri-Fernández R, González A, Lerma E, Guelar A, et al. Effect of Probiotics (Saccharomyces boulardii) on Microbial Translocation and Inflammation in HIV-Treated Patients. JAIDS J Acquir Immune Defic Syndr. 2015;68(3):256–63.

138. Hummelen R, Changalucha J, Butamanya NL, Cook A, Habbema JDF, Reid G. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int J Gynecol Obstet. 2010;111(3):245–8.

139. Kazemi A, Djafarian K, Speakman JR, Sabour P, Soltani S, Shab-Bidar S. Effect of Probiotic Supplementation on CD4 Cell Count in HIV-Infected Patients: A Systematic Review and Meta-analysis. J Diet Suppl. 2018;15(5):776–88.

140. Yang OO, Kelesidis T, Cordova R, Khanlou H. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic
double-blind placebo-controlled trial. AIDS Res Hum Retroviruses. 2014;30(10):988–95.

141. Stiksrud B, Nowak P, Nwosu FC, Kvale D, Thalme A, Sonnerborg A, et al. Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. J Acquir Immune Defic Syndr. 2015;70(4):329–37.

142. Ceccarelli G, Fratino M, Selvaggi C, Giustini N, Serafino S, Schietroma I, et al. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients. Brain Behav. 2017;7(8):e00756.

143. Villar-García J, Güerri-Fernández R, Moya A, Gonzalez A, Hernandez JJ, Lerma E, et al. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PLoS One. 2017;12(4):e0173802.

144. González-Hernández LA, Jave-Suarez LF, Fafutis-Morris M, Montes-Salcedo KE, Valle-Gutierrez LG, Campos-Loza AE, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: A double-blind randomized controlled pilot trial. Nutr J. 2012;11(1):90.

145. Arnbjerg CJ, Vestad B, Hov JR, Pedersen KK, Jespersen S, Johannesen HH, et al. Effect of lactobacillus rhamnosus GG supplementation on intestinal inflammation assessed by PET/MRI scans and Gut microbiota composition in HIV-infected individuals. J Acquir Immune Defic Syndr. 2018;78(4):450–7.
146. D’Ettorre G, Ceccarelli G, Giustini N, Serafino S, Calantone N, De Girolamo G, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: Results of the “Probio-HIV” clinical trial. PLoS One. 2015;10(9):e0137200.

147. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.

148. Hummelen R, Changalucha J, Butamanya NL, Koyama TE, Cook A, Habbema JDF, et al. Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes. 2011;2(2):80–5.

149. Hummelen R, Hemsworth J, Changalucha J, Butamanya NL, Hekmat S, Habbema JDF, et al. Effect of micronutrient and probiotic fortified yogurt on immune-function of anti-retroviral therapy naive HIV patients. Nutrients. 2011;3(10):897–909.

150. D’Ettorre G, Rossi G, Scagnolari C, Andreotti M, Giustini N, Serafino S, et al. Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients. Immun Inflamm Dis. 2017;5(3):244–60.

151. Moroti C, Magri LFS, de Rezende Costa M, Cavallini DCU, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012;11(1):29.
152. Hemsworth JC, Hekmat S, Reid G. Micronutrient supplemented probiotic yogurt for HIV-infected adults taking HAART in London, Canada. Gut Microbes. 2012;3(5):414–9.

153. Schunter M, Chu H, Hayes TL, McConnell D, Crawford SS, Luciw PA, et al. Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection. BMC Complement Altern Med. 2012;12(1):84.

154. Serrano-Villar S, De Lagarde M, Vázquez-Castellanos J, Vallejo A, Bernadino JI, Madrid N, et al. Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study). Clin Infect Dis. 2019;68(1):120–30.

155. Santos AS e. A de C, Silveira EA da, Falco MO, Nery MW, Turchi MD. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized clinical trial. Clin Nutr. 2017;36(3):680–5.

156. Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017;46(1):171–85.

157. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation. Am J Gastroenterol. 2012;107(11):1755.

158. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous. Surgery. 1958;44(5):854–9.

159. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146(6):1547–53.
160. Kuijper EJ, Coignard B, Tüll P, Poxton I, Brazier J, Duerden B, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(12 Suppl. 6):2–18.

161. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile –Associated Diarrhea. J Infect Dis. 2008;197(3):435–8.

162. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002.

163. Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–43.

164. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065–71.

165. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for clostridium difficile infection: Systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–8.

166. Smits LP, Bouter KEC, De Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946–53.
167. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014;146(6):1573–82.

168. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology. 2017;152(4):799-811.e7.

169. Tan X, Johnson S. Fecal microbiota transplantation (FMT) for C. difficile infection, just say ‘No.’ Anaerobe. 2019;60(1):102092.
FIGURE LEGENDS

**Fig1.** In normal physiological conditions, the microorganisms are in the intestinal lumen interacting with the intestinal cells in a state of symbiosis but, when HIV infection occurs, depletion of lymphocytes T CD4 takes place in the GALT (gut-associated lymphoid tissue). This is accompanied by a rupture of the epithelial barrier, which triggers alterations in the intestinal lumen and also in the composition of the microbiota (at least at bacteria level) (27). This dysbiosis favors the passage of microorganisms and their components to the *lamina propria* and, hence, to the circulation, which is known as bacterial translocation (BT), which undergoes subsequent intestinal and systemic inflammation (28). **A)** Gut homeostasis. **B)** Gut dysbiosis after HIV infection.

Original. Made with *PowerPoint*.

**Fig2.** General scheme of atheroma plaque formation and effects of HIV infection (in Arabic numbers). Modified from *Alonso-Villaverde Lozano* (2009) (44). MHC II (major histocompatibility complex class II); TCRs (T-cell receptors); MCP-1 (monocyte chemoattractant protein 1); VCAM-1 (vascular cell adhesion molecule 1).

Original. Made with *Biorender*.

**Fig3.** Processing pathway of choline, carnitine and betaine from diet to produce TMAO and clinical effects of TMAO. TMA (trimethylamine); TMAO (trimethylamine N-oxide).

Original. Made with *Biorender*.

**Fig4.** sCD14 is secreted by activated monocytes after the join of LPS to the TLR-4/MD-2 complex mediated by LBP and mCD14. sCD14 can join in turn to more LPS and transfer it to mCD14 triggering the cascade activation of a greater number of monocytes. sCD163 acts in the immune system but it is not yet clearly defined how. LPS (lipopolysaccharide); TLR-4 (toll-like receptor 4); LBP (lipopolysaccharide binding protein); sCD14 (soluble CD14); mCD14 (membrane CD14); sCD163 (soluble CD163).

Original. Made with *PowerPoint*. 
**TABLES**

**Table 1.** Summary of the main cardiovascular risk markers characterized in HIV patients. (↑) HIV patients present higher levels than general population. (↓) HIV patients present lower levels than general population. (¿?) Controversial results.

| Dependent on microbiota | Independent on microbiota |
|--------------------------|---------------------------|
| ↑ TMAO ¿?                | ↑ Endothelin-1             |
| ↑ Carnitine              | ↓ PON-1 activity ¿?       |
| ↑ Betaine                | ↑ ADMA                    |
| ↑ Kynurenine/Trp ratio   | ↑ Lp-PLA2 ¿?              |
| ↑ sCD14                  | ↓ CD4/CD8 ratio           |
| ↑ sCD163                 |                           |
| ↑ D-dimer                |                           |
| ↑ IL-6                   |                           |
| ↑ IL-1Ra                 |                           |
| ↑ RANTES                 |                           |

BT (bacterial translocation); TMAO (trimethylamine N-oxide); Trp (tryptophan); sCD14 (soluble CD14), sCD163 (soluble CD163); IL-6 (interleukin-6); IL-1Ra (interleukin-1 receptor antagonist); PON-1 (paraoxonase-1); ADMA (asymmetric dimethylarginine); Lp-PLA2 (Lipoprotein-associated phospholipase A2).
Table 2. Clinical trials registered in ClinicalTrials.gov (42).

| NCT number | Country  | Associated article | State        | Intervention                          | Number of participants | Age of participants | Objective                                                   | Main outcomes                                                                 |
|------------|----------|--------------------|--------------|---------------------------------------|------------------------|--------------------|-------------------------------------------------------------|------------------------------------------------------------------------------|
| NCT01838915 | Spain    | (132)              | Completed    | scGOS/lcFOS + glutamine               | 45                     | 18-70 years        | To assess the effects in naïve and ART-treated HIV-infected patients on: | Safe  
|            |          |                    |              | 6 weeks                               |                        |                    | • Safety  
|            |          |                    |              |                                       |                        |                    | • Gut microbiota composition  
|            |          |                    |              |                                       |                        |                    | • Bacterial translocation  
|            |          |                    |              |                                       |                        |                    | • Immune activation  
|            |          |                    |              |                                       |                        |                    | • Endothelial dysfunction  
|            |          |                    |              |                                       |                        |                    | • Safe  
|            |          |                    |              |                                       |                        |                    | • Modification of gut microbiota composition only in naïve patients  
|            |          |                    |              |                                       |                        |                    | • Decrease of the activation of lymphocytes T CD4 in naïve and ART-treated patients |
| NCT04058392 | Canada   | No                 | Not yet recruiting | Camu Camu (2 capsules/day)            | 22 (enrolled)          | 18 years and older | To evaluate the effects in ART-treated HIV-infected patients on: |                               |
|            |          |                    |              |                                       |                        |                    | • Tolerance  
|            |          |                    |              |                                       |                        |                    | • Gut microbiota composition  
|            |          |                    |              |                                       |                        |                    | • Inflammation  
|            |          |                    |              |                                       |                        |                    | • Changes of gut barrier  |

scGOS (short chain galactooligosaccharides); lcFOS (long chain fructooligosaccharides); HIV (human immunodeficiency virus); ART (antiretroviral treatment).
### Table 3. Clinical trials registered in ClinicalTrials.gov (42).

| NCT number | Country          | Associated article | State    | Intervention                                                                 |
|------------|------------------|--------------------|----------|------------------------------------------------------------------------------|
| NCT02164344 | Italy            | Unknown            |          | *S. salivarius* spp. *thermophilus* 2'04x10^{14} CFU, *B. breve, B. infantis, B. longum* 9'3x10^{13} CFU, *L. acidophilus* 2x10^{12} CFU, *L. plantarum* 2'2x 10^{8} CFU, *L. casei* 2'2x10^{9} CFU, *L. delbrueckii* spp. *Bulgaris* 3x10^{8} CFU and *S. faecium* 3x10^{7} CFU 1 daily dose 48 weeks |
| NCT01439841 | Norway and Sweden| Completed          |          | *Biola® (L. rhamnosus* GG 10^{8} CFU, *L. acidophilus* La-5 10^{7} CFU and *B. animalis* subsp. lactis Bb-12 10^{9} CFU) 1 daily dose 8 weeks |
| NCT00517803 | Canada           | No                 | Completed| *Probiotic yogurt* (175 g) 1 daily yogurt 16 weeks |
| NCT02448238 | USA              | No                 | Completed| *VSL#3® (S. thermophilus, B. breve, B. longum, B. infantis, L. plantarum, L. acidophilus, L. paracasei and L. bulgaricus* (9x10^{11} CFU)) 1 daily dose |

| Number of participants | Age of participants | Objective                                                                 | Main outcomes                                                                 |
|------------------------|---------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| 30                     | 18-75 years         | To determine the effects in ART-treated HIV-infected patients on:            | • Safe<br> • Decrease of LBP levels<br> • Increase of lymphocytes T CD4<br> • Decrease of the activation markers CD38 and HLA-DR presented on lymphocytes T CD4 |
| 32                     | 18 years and older  | To investigate the effects in ART-treated HIV-infected patients on:         | • Modification of gut microbiota composition<br> • Decrease of D-dimer and IL-6 levels |
| 24                     | 18-85 years         | To compare the effects of several levels of fortified probiotic yogurt vs. placebo in HIV-infected patients with cancer on: | • Inflammation<br> • Immune function |
| 23                     | 18 years and older  | To assess the effects in naïve HIV-infected Malian women on:               | • Safety, tolerability and level of stress<br> • Inflammation |
| NCT number | Country | Associated article | State | Intervention | Number of participants | Age of participants | Objective | Main outcomes |
|------------|---------|-------------------|-------|--------------|------------------------|---------------------|-----------|--------------|
| NCT02764684 | Denmark | No | Completed | *L. rhamnosus*<br>2 daily doses<br>8 weeks | 45 | 18 years and<br>olders | • Bacterial translocation<br>• Immune function | To evaluate the effects in *naive* HIV-infected patients on:<br>• Gut microbiota composition<br>• Microbial translocation<br>• Lipid metabolism<br>• Cardiovascular risk factors<br>• Systemic and gut inflammation |
| NCT02441231 | Canada | No | Unknown | Visbiome®<br>2 daily doses (9x10^{14} CFU/day)<br>48 weeks | 36 (only males) | 19 years and<br>olders | To investigate the effects in *ART-treated* HIV-infected men on:<br>• Microbial translocation<br>• Immune cells function and activation |
| NCT00536848 | Tanzania | (138) | Unknown | *L. rhamnosous* GR-1 and *L. reuteri*<br>RC-14 (2x10^{9} CFU)<br>1 daily dose<br>24 weeks | 65 (only females) | 18-45 years | To determine the effects in *naive* HIV-infected women with vaginosis on:<br>• Diarrhea<br>• Immune system<br>• Bacterial vaginosis | • No improvements in bacterial vaginosis |
| NCT01908049 | Spain | (137) | Unknown | *S. boulardii*<br>3 daily doses<br>12 weeks | 44 | 18 years and<br>olders | To assess the effects in *ART-treated* HIV-infected patients on:<br>• Bacterial translocation<br>• Gut microbiota composition | • Decrease of IL-6 and LBP levels |
| NCT number     | Country | Associated article | State    | Intervention                                                                 | Number of participants | Age of participants | Objective                                                                                           | Main outcomes                                                                                                                                 |
|----------------|---------|--------------------|----------|------------------------------------------------------------------------------|------------------------|---------------------|----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| NCT02706717    | USA     | No                 | Completed| Visbiome®<br>1 daily dose<br>24 weeks                                        | 93                     | 18 years and elders | To evaluate the effects in ART-treated HIV-infected patients on:<br>• Immune function<br>• Viral load            |                                                                                                                                                  |
| NCT02276326    | Italy   | (142)              | Recruiting| VSL#3® (<em>S. thermophilus, B. breve, B. longum, B. infantis, L. plantarum, L. acidophilus, L. paracasei and L. bulgaricus</em> (9x10<sup>11</sup> CFU))<br>4 daily doses<br>16 weeks | 20                     | 18 years and elders | To determine the effects in ART-treated HIV-infected patients on:<br>• Inflammation<br>• Modification of microbiota composition<br>• Improvement of neurocognitive profile |                                                                                                                                                  |
| NCT02640625    | Norway  | No                 | Completed| <em>L. rhamnosus GG, L. acidophilus, L. bulgaricus, B. animalis subsp. lactis and S. thermophilus</em><br>1 daily dose<br>10 weeks | 60                     | 25-65 years<br>(only males) | To assess the effects in ART-treated HIV-infected men on:<br>• Safety<br>• Biological effects<br>To investigate differences between IR and INR in:<br>• Microbial composition<br>• Mucosal barrier function |                                                                                                                                                  |
| NCT01184456    | USA     | No                 | Completed| GanedenBC30® (<em>Bacillus coagulans</em> GBI-30 and PTA-6086 (2x10<sup>12</sup> CFU))<br>1 daily dose<br>12 weeks | 24                     | 18 years and elders | To evaluate the effects in ART-treated HIV-infected patients on:<br>• Bacterial translocation |                                                                                                                                                  |
| NCT04297501    | China   | No                 | Completed| <em>Bifidobacterium</em> (3x10<sup>12</sup>) and <em>Lactobacillus</em> (10<sup>12</sup>)<br>1 daily dose | 50                     | 18-65 years | To investigate the effects in ART-treated HIV-infected patients on:                                                                 |                                                                                                                                                  |
| NCT number | Country | Associated article | State | Intervention | Number of participants | Age of participants | Objective | Main outcomes |
|------------|---------|--------------------|-------|--------------|-----------------------|---------------------|-----------|---------------|
|            |         |                    |       | 12 months    |                       |                     |           | Microbial composition and diversity |
|            |         |                    |       |              |                       |                     |           | Immune recovery and activation |
|            |         |                    |       |              |                       |                     |           | Gut damage |
|            |         |                    |       |              |                       |                     |           | Microbial translocation |
|            |         |                    |       |              |                       |                     |           | Inflammation |
| NCT04297488 | China   | No                 | Not yet recruiting | *Bifidobacterium* (3x10^{12}) and *Lactobacillus* (10^{12}) | 20 | 18-65 years | To explore the effects in INR HIV-infected patients on: | • Microbial composition and diversity • Immune recovery and activation • Gut damage • Microbial translocation • Inflammation |
|            |         |                    |       | 1 daily dose |                       |                     |           | |
|            |         |                    |       | 6 months     |                       |                     |           | |
|            |         |                    |       |              |                       |                     |           | |
|            |         |                    |       |              |                       |                     |           | |
| NCT04175223 | France  | No                 | Not yet recruiting | Vivomixx® | 50 | 18 years and older | To evaluate the effects in ART-treated HIV-infected patients with neurocognitive disorders on: | • Immune activation • Cognitive performance |
|            |         |                    |       | 2 daily doses |                       |                     |           | |
|            |         |                    |       | 6 months     |                       |                     |           | |
|            |         |                    |       |              |                       |                     |           | |
|            |         |                    |       |              |                       |                     |           | |
| NCT0409943 | Italy   | No                 | Recruiting | Vivomixx® | | | | To assess the effects in ART-treated HIV-infected patients with HPV genital infection on: | • Anal HPV clearance • Anal dysplasia |
|            |         |                    |       | 4 daily doses |                       |                     |           | |
|            |         |                    |       | 6 months     |                       |                     |           | |

CFU (colony forming unit); HIV (human immunodeficiency virus); ART (antiretroviral treatment); IR (immunological responder); INR (immunological non-responder); IL-6 (interleukin-6); HPV (human papillomavirus).
| NCT number | Country    | Associated article | State   | Intervention                                                                 | Number of participants | Age of participants | Objective                                                                 | Main outcomes                                                                 |
|-----------|------------|--------------------|---------|------------------------------------------------------------------------------|------------------------|---------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| NCT03009032 | Spain      | (154)              | Completed | PMT25341® 1 daily dose 48 weeks                                              | 77                     | 18-80 years          | To investigate the effects of the intervention in naïve HIV-infected patients who initiate ART on: Safety, Immunological recovery, Inflammatory markers, Gut microbiota composition | • No effects on microbiota composition.  
• No effects on lymphocytes T CD4.  
• No effects on markers of inflammation and bacterial translocation. |
| NCT00688311 | USA        | (153)              | Completed | Synbiotic 2000® (4 probiotic bacteria (10^10 CFU/bacteria) + 4 dietary fibers (2.5 g/fiber)) 1 daily dose 4 weeks | 34 (only females)      | 18 years and older   | To determine the effects in ART-treated HIV-infected women on: Intestinal function, Immune system overactivation, Immune function | • Safe  
• Modification of gut microbiota composition |
| NCT03568812 | Indonesia  | No Recruiting      | Recruiting | Rillus® (L. plantarum 8’55 mg, S. thermophilus 8’55 mg and B. bifidum 2’55 mg (10^8 CFU) + FOS 480 mg) 1 daily dose 4 weeks | 80                     | 18-55 years          | To assess the effects INR HIV-infected patients on: Gut mucosal integrity and immunity, Bacterial translocation, Gut inflammation | |
| NCT03542786 | Spain      | No Recruiting      | Recruiting | 13.1® (L. plantarum CECT7484, L. plantarum CECT7485 and P. acidilactici) + ProSheed® 1 daily dose 12 weeks | 40                     | 18 years and older   | To evaluate the effects in ART-treated HIV-infected patients on: Inflammaging (premature aging) | |
| NCT02180035 | Brazil     | (155)              | Completed | Lactobacillus paracasei, Lactobacillus                                        | 290                    | 19 years and older   | To investigate the effects in ART-treated HIV-infected patients on: Lipid metabolism | • Reduction of diarrhea, nausea and/or vomits, constipation and dyspepsia |
| NCT number | Country | Associated article | State | Intervention | Number of participants | Age of participants | Objective | Main outcomes |
|------------|---------|-------------------|-------|--------------|------------------------|--------------------|------------|--------------|
|            |         |                   |       | *Lactobacillus rhamnosus*, *Lactobacillus acidophilus* and *Bifidobacterium lactis* + FOS | 2 daily doses 24 weeks |                    |            |              |

CFU (colony forming unit); HIV (human immunodeficiency virus); ART (antiretroviral treatment); INR (immunological non-responder).
### Table 5. Clinical trials registered in ClinicalTrials.gov (42).

| NCT number | Country | Associated article | State | Intervention | Number of participants | Age of participants | Objective | Main outcomes |
|------------|---------|-------------------|-------|--------------|------------------------|-------------------|-----------|---------------|
| NCT02256592 | USA     | No                | Completed | 300 ml of fecal suspension from a healthy donor delivered by colonoscopy and provided by OpenBiome | 18 | 18-75 years | To examine the safety and durability of the intervention | To determine the effects in ART-treated HIV-infected patients on:  
  - Immune activation  
  - Inflammatory biomarkers |
| NCT03329560 | USA     | No                | Active, not recruiting | PRIM-DJ2727 (capsules containing lyophilized microbiota derived from 150 g of healthy donor stool)  
  1 daily dose  
  6 weeks | 6 (enrolled) | 18 years and older | To evaluate if the intervention is safe for ART-treated HIV-infected MSM |
| NCT03008941 | Spain   | No                | Completed | FT capsules provided by OpenBiome  
  10 capsules first week + 5 capsules weekly  
  8 weeks | 30 | 18-80 years | To assess the effects in ART-treated HIV-infected patients on:  
  - Bacterial metabolism  
  - Plasma metabolite fingerprint  
  - Immune function and activation  
  - Inflammatory markers  
  - Markers of enterocyte barrier function |
| NCT04165200 | Mexico  | No                | Completed | FT through frozen capsules  
  15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start | 22 | 18 years and older | To monitor the effects in naïve HIV-infected patients who initiate ART on:  
  - Lymphocytes T CD4  
  - Viral load during week 0, 4, 8, 12 and 24 after ART start |

FT (fecal transplantation); HIV (human immunodeficiency virus); ART (antiretroviral treatment); MSM (men who have sex with men).